Results for Chemicals & Small Molecules ( 97587 )
- From: DKK1,335.00
MK-3207 (Legacy Tebubio ref. 282T21558). MK-3207 is a potent and orally bioavailable CGRP receptor antagonist (IC 50 = 0.12 nM; K i = 0.024 nM); highly selective versus human AM1, AM2, CTR, and AMY3. IC50 Value: 0.024 nM (Ki, Human CGRP) [1] As other CGRP receptor antagonists, MK-3207 shows a lower affinity for human CGRP receptors from other species, including canine and rodent. in vitro: MK-3207 is a potent antagonist of the human and rhesus monkey CGRP receptors (K(i) = 0.024 nM). in vivo: MK-3207 produced a concentration-dependent inhibition of dermal vasodilation, with plasma concentrations of 0.8 and 7 nM required to block 50 and 90% of the blood flow increase, respectively. The tritiated analog [3H]MK-3207 was used to study the binding characteristics on the human CGRP receptor. [3H]MK-3207 displayed reversible and saturable binding (K(D) = 0.06 nM), and the off-rate was determined to be 0.012 min(-1), with a t(1/2) value of 59 min [1]. After the first interim analysis, the two
- Ref: T21559Sizes: 1 mg, 5 mg, 25 mg, 100 mg, 50 mg, 10 mg, 2 mg, 1 mL * 10 mM (in DMSO)
- From: DKK375.00
WP1066 (Legacy Tebubio ref. 282T2156). WP1066 is a inhibitor of JAK2 (IC50: 2.30 μM) and STAT3 (IC50: 2.43 μM) in HEL cells; shows activity to JAK2, STAT3/5, and ERK1/2, not JAK1 and JAK3. WP1066 has been used in trials studying the treatment of Melanoma, Brain Cancer, Solid Tumors, and Central Nervous System Neoplasms.
- From: DKK623.00
WAY-100635 (Legacy Tebubio ref. 282T21561). WAY-100635 is a potent and selective 5-hydroxytryptamine 1A (5-HT1A) receptor antagonist with an IC50 of 0.91 nM and Ki of 0.39 nM, exhibiting pIC50 values of 8.9 and 6.6 for 5-HT1A and α1-adrenergic receptors, respectively. Additionally, WAY-100635 acts as a potent agonist of the dopamine D4 receptor [1] [2] [3].
- From: DKK1,305.00
Cyclosomatostatin Acetate (Legacy Tebubio ref. 282T21567L). Cyclosomatostatin Acetate is an effective antagonist of the somatostatin receptor.Cyclosomatostatin Acetate inhibits SSTR1 signaling and decreases cell proliferation, ALDH+ cell population size, and sphere-formation in colorectal cancer cells.